Endoform Natural Demonstrates Significant Healing Advantage for Venous Leg Ulcers in Large Real-World Study

Aroa Biosurgery (搜索)搜索该词条 has reached a significant clinical evidence milestone with the publication of a large real-world study demonstrating superior efficacy of its Endoform Natural (搜索)搜索该药品 product in treating venous leg ulcers (搜索)搜索该疾病 (VLUs (搜索)搜索该疾病), one of the most challenging wound types in clinical practice.

The retrospective analysis, published in the International Wound Journal in April 2025, compared 470 VLUs (搜索)搜索该疾病 treated with Endoform Natural (搜索)搜索该药品 against 360 VLUs treated with a leading reconstituted collagen dressing. Data was collected from 223 wound care centers across the United States with minimal inclusion or exclusion criteria to ensure real-world applicability.

Results showed that VLUs (搜索)搜索该疾病 treated with Endoform Natural (搜索)搜索该药品 healed approximately eight weeks faster than those in the comparator group. Additionally, patients receiving Endoform Natural demonstrated significantly improved healing probabilities overall.

Understanding Venous Leg Ulcers

VLUs (搜索)搜索该疾病 represent a significant clinical challenge, characterized as open sores that develop due to impaired blood flow in the legs. These wounds are notoriously difficult to treat, with only about 40% healing after three months of standard therapy. They also have high recurrence rates, creating a substantial burden for both patients and healthcare systems.

"These types of wounds are extremely debilitating and painful for patients," explained Dr. Barnaby May, Chief Scientific Officer at Aroa. "The chronic nature of VLUs (搜索)搜索该疾病 significantly impacts quality of life and creates substantial ongoing healthcare costs."

Real-World Evidence Approach

The study represents a growing trend toward using real-world evidence (RWE) to validate clinical performance of medical devices and treatments. Unlike traditional randomized controlled trials, RWE studies can incorporate much larger patient populations and reflect actual clinical practice conditions.

"There is a growing awareness of RWE studies to validate clinical performance," noted Dr. May. "These types of studies enable much larger patient numbers to be compared versus traditional randomized controlled trials. Given that RWE studies use data from 'real-world' use of a treatment, the results can be more meaningful, especially in wound care where there is a high degree of variability in how wounds are cared for and patient factors."

The study's design, which minimized inclusion and exclusion criteria, allowed researchers to capture data that more accurately reflects the diverse patient populations and treatment approaches seen in everyday clinical settings.

Clinical Implications

The eight-week acceleration in healing time represents a substantial clinical benefit, particularly for a condition as challenging as VLUs (搜索)搜索该疾病. Faster healing translates to reduced pain, lower infection risk, improved mobility, and enhanced quality of life for patients.

Dr. Gregory Bohn, who participated in the research, shared his personal clinical experience: "I was first introduced to Endoform in 2012 and started using the product to treat my own patients with VLUs (搜索)搜索该疾病. This new data validates what I have seen in my own practice managing VLUs with Endoform."

Economic Impact

Beyond the clinical benefits, the study highlights potential economic advantages. The significant reduction in healing time could translate to substantial cost savings for healthcare systems by reducing the need for prolonged wound care, decreasing complication rates, and potentially lowering hospitalization requirements.

"The striking difference in the healing outcomes demonstrate the potential for considerable cost reductions and improvements in patient quality of life, due to the significant improvements seen when VLUs (搜索)搜索该疾病 were treated using Endoform Natural (搜索)搜索该药品," the company stated in their announcement.

Building on Previous Evidence

This study builds upon Aroa's growing body of clinical evidence. It represents the company's second large retrospective RWE study comparing Endoform Natural (搜索)搜索该药品 to a leading reconstituted collagen dressing. A previous analysis of over 2,200 diabetic foot ulcers (搜索)搜索该疾病 (DFUs (搜索)搜索该疾病) demonstrated similarly impressive results, with significantly faster healing of DFUs when treated with Endoform Natural.

The publication marks a milestone for Aroa Biosurgery (搜索)搜索该词条, bringing the total number of peer-reviewed studies supporting their proprietary AROA ECM (搜索)搜索该靶点 (Extracellular Matrix) technology to over 100.

About Endoform Natural

Endoform Natural (搜索)搜索该药品 utilizes Ovine Forestomach Matrix (搜索)搜索该药品 technology, which appears to provide advantages over traditional reconstituted collagen dressings. While the exact mechanisms behind its superior performance weren't detailed in the announcement, the consistent results across multiple wound types suggest fundamental advantages in the product's approach to tissue regeneration.

The technology appears particularly effective in challenging wound environments, including those with compromised vascular function like VLUs (搜索)搜索该疾病, which traditionally respond poorly to standard treatments.

Future Directions

With two large RWE studies now demonstrating superior outcomes for both VLUs (搜索)搜索该疾病 and DFUs (搜索)搜索该疾病, Aroa Biosurgery (搜索)搜索该词条 appears well-positioned to expand the clinical adoption of Endoform Natural (搜索)搜索该药品. The growing body of evidence supporting the product's efficacy in difficult-to-treat wounds could potentially influence treatment guidelines and reimbursement decisions.

As healthcare systems increasingly emphasize evidence-based practice and value-based care, products with demonstrated superior outcomes in real-world settings may gain competitive advantages in the wound care market.